U.S., April 14 -- ClinicalTrials.gov registry received information related to the study (NCT07526857) titled 'Epivascular Glia Regression and Macular Pigment Restoration After Faricimab in Diabetic Retinopathy' on April 07.
Brief Summary: The aim of the study is to evaluate in diabetic patients affected by diabetic retinopathy epivascular glia regression and macular pigment restoration after faricimab injection in diabetic retinopathy in a 1 year follow up
Study Start Date: Jan. 01, 2025
Study Type: OBSERVATIONAL
Condition:
Diabetic Retinopathy, DR
Intervention:
DRUG: Faricimab Injection [Vabysmo]
One group treated with faricimab and the other one treated with Aflibercept
DRUG: Aflibercept (2.0 mg)
Aflibercept 2 mg intravitreal in...